27175597|t|Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.
27175597|a|Copper-ionophores that elevate intracellular bioavailable copper display significant therapeutic utility against prostate cancer cells in vitro and in TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mice. However, the pharmacological basis for their anticancer activity remains unclear, despite impending clinical trails. Herein we show that intracellular copper levels in prostate cancer, evaluated in vitro and across disease progression in TRAMP mice, were not correlative with copper-ionophore activity and mirrored the normal levels observed in patient prostatectomy tissues (Gleason Score 7 & 9). TRAMP adenocarcinoma cells harbored markedly elevated oxidative stress and diminished glutathione (GSH)-mediated antioxidant capacity, which together conferred selective sensitivity to prooxidant ionophoric copper. Copper-ionophore treatments [CuII(gtsm), disulfiram & clioquinol] generated toxic levels of reactive oxygen species (ROS) in TRAMP adenocarcinoma cells, but not in normal mouse prostate epithelial cells (PrECs). Our results provide a basis for the pharmacological activity of copper-ionophores and suggest they are amendable for treatment of patients with prostate cancer. Additionally, recent in vitro and mouse xenograft studies have suggested an increased copper requirement by prostate cancer cells. We demonstrated that prostate adenocarcinoma development in TRAMP mice requires a functional supply of copper and is significantly impeded by altered systemic copper distribution. The presence of a mutant copper-transporting Atp7b protein (tx mutation: A4066G/Met1356Val) in TRAMP mice changed copper-integration into serum and caused a remarkable reduction in prostate cancer burden (64% reduction) and disease severity (grade), abrogating adenocarcinoma development. Implications for current clinical trials are discussed.
27175597	0	6	Copper	Chemical	MESH:D003300
27175597	23	38	prostate cancer	Disease	MESH:D011471
27175597	53	59	copper	Chemical	MESH:D003300
27175597	105	111	copper	Chemical	MESH:D003300
27175597	126	132	Copper	Chemical	MESH:D003300
27175597	184	190	copper	Chemical	MESH:D003300
27175597	239	254	prostate cancer	Disease	MESH:D011471
27175597	277	282	TRAMP	Disease	MESH:D000230
27175597	295	327	Adenocarcinoma of Mouse Prostate	Disease	MESH:D000230
27175597	329	333	mice	Species	10090
27175597	486	492	copper	Chemical	MESH:D003300
27175597	503	518	prostate cancer	Disease	MESH:D011471
27175597	573	578	TRAMP	Disease	MESH:D000230
27175597	579	583	mice	Species	10090
27175597	611	617	copper	Chemical	MESH:D003300
27175597	680	687	patient	Species	9606
27175597	733	753	TRAMP adenocarcinoma	Disease	MESH:D000230
27175597	819	830	glutathione	Chemical	MESH:D005978
27175597	832	835	GSH	Chemical	MESH:D005978
27175597	940	946	copper	Chemical	MESH:D003300
27175597	948	954	Copper	Chemical	MESH:D003300
27175597	977	987	CuII(gtsm)	Chemical	-
27175597	989	999	disulfiram	Chemical	MESH:D004221
27175597	1002	1012	clioquinol	Chemical	MESH:D007464
27175597	1040	1063	reactive oxygen species	Chemical	MESH:D017382
27175597	1065	1068	ROS	Chemical	MESH:D017382
27175597	1073	1093	TRAMP adenocarcinoma	Disease	MESH:D000230
27175597	1119	1124	mouse	Species	10090
27175597	1224	1230	copper	Chemical	MESH:D003300
27175597	1290	1298	patients	Species	9606
27175597	1304	1319	prostate cancer	Disease	MESH:D011471
27175597	1355	1360	mouse	Species	10090
27175597	1407	1413	copper	Chemical	MESH:D003300
27175597	1429	1444	prostate cancer	Disease	MESH:D011471
27175597	1473	1496	prostate adenocarcinoma	Disease	MESH:D000230
27175597	1512	1517	TRAMP	Disease	MESH:D000230
27175597	1518	1522	mice	Species	10090
27175597	1555	1561	copper	Chemical	MESH:D003300
27175597	1611	1617	copper	Chemical	MESH:D003300
27175597	1657	1663	copper	Chemical	MESH:D003300
27175597	1677	1682	Atp7b	Gene	11979
27175597	1705	1711	A4066G	DNAMutation	tmVar:g|SUB|A|4066|G;HGVS:g.4066A>G;VariantGroup:0;OriginalGene:11979;CorrespondingGene:540;RS#:1258675855;CorrespondingSpecies:10090
27175597	1712	1722	Met1356Val	ProteinMutation	tmVar:p|SUB|M|1356|V;HGVS:p.M1356V;VariantGroup:1;OriginalGene:11979;CorrespondingGene:540;CorrespondingSpecies:10090
27175597	1727	1732	TRAMP	CellLine	CVCL:B459
27175597	1733	1737	mice	Species	10090
27175597	1746	1752	copper	Chemical	MESH:D003300
27175597	1813	1828	prostate cancer	Disease	MESH:D011471
27175597	1893	1907	adenocarcinoma	Disease	MESH:D000230
27175597	Association	MESH:D003300	RS#:1258675855;HGVS:g.4066A>G;CorrespondingGene:540
27175597	Negative_Correlation	MESH:D000230	HGVS:p.M1356V;CorrespondingGene:540
27175597	Negative_Correlation	RS#:1258675855;HGVS:g.4066A>G;CorrespondingGene:540	MESH:D000230
27175597	Association	MESH:D003300	RS#:1258675855;HGVS:g.4066A>G;CorrespondingGene:540
27175597	Negative_Correlation	RS#:1258675855;HGVS:g.4066A>G;CorrespondingGene:540	MESH:D011471
27175597	Association	MESH:D000230	11979
27175597	Association	MESH:D003300	HGVS:p.M1356V;CorrespondingGene:540
27175597	Association	MESH:D003300	MESH:D000230
27175597	Association	MESH:D003300	11979
27175597	Association	MESH:D011471	11979
27175597	Negative_Correlation	MESH:D000230	RS#:1258675855;HGVS:g.4066A>G;CorrespondingGene:540
27175597	Negative_Correlation	MESH:D011471	HGVS:p.M1356V;CorrespondingGene:540
27175597	Positive_Correlation	MESH:D007464	MESH:D017382
27175597	Negative_Correlation	MESH:D011471	RS#:1258675855;HGVS:g.4066A>G;CorrespondingGene:540
27175597	Positive_Correlation	MESH:D003300	MESH:D017382
27175597	Association	MESH:D003300	MESH:D011471
27175597	Negative_Correlation	MESH:D005978	MESH:D000230
27175597	Positive_Correlation	MESH:D004221	MESH:D017382
27175597	Association	MESH:D000230	540
27175597	Association	MESH:D011471	540

